L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa
Open Access
- 7 October 2026
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Abstract
The prevalence of non-susceptibility to ceftolozane-tazobactam (C/T) among Pseudomonas aeruginosa remains low, but novel mechanisms of C/T resistance are of concern. Herein, we describe a novel P. aeruginosa genotype associated with high-level C/T resistance (>256/4 µg/mL) in a single patient. Whole-genome sequencing of the isolate was compared to that of a susceptible isolate cultured from the same patient 2 months earlier. Analysis of the sequences revealed two different P. aeruginosa high-risk clones: sequence type (ST)111 followed by ST235. The C/T-resistant ST235 isolate contained five copies of a genetic element composed of an L2 β-lactamase gene ( bla L2 ) and a truncated ampR L2 transcriptional regulator gene, which are commonly found together in Stenotrophomonas maltophilia strains and have not been reported to mediate resistance to C/T. Comparative genomic analysis with other P. aeruginosa isolates failed to identify alternative explanations for the observed C/T resistance. We found that exogenous expression of bla L2 increased C/T minimum inhibitory concentrations (MICs) in genetically distinct P. aeruginosa strains. A screen of our archived isolates identified two P. aeruginosa clinical isolates, PS2045 and PS2046, with one and two copies, respectively, of the genetic element containing bla L2 and truncated ampR L2 . Interestingly, disruption of the gene bla L2 but not the truncated ampR L2 in PS2045 led to a decrease in C/T MIC. Thus, we report a novel mechanism of C/T resistance in P. aeruginosa partially mediated by an L2 β-lactamase independently of its canonical regulator, AmpR L2 .Keywords
Funding Information
- National Institutes of Health (R01AI118257)
- National Institutes of Health (R01AI158530)
- National Institutes of Health (U19AI135964)
This publication has 66 references indexed in Scilit:
- Complex pathways to ceftolozane-tazobactam resistance in clinical Pseudomonas aeruginosa isolates: a genomic epidemiology studyClinical Microbiology and Infection, 2025
- Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018International Journal of Infectious Diseases, 2021
- Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)International Journal of Antimicrobial Agents, 2021
- Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experienceInternational Journal of Antimicrobial Agents, 2019
- Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic IslandsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2018
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β‐Lactamase Inhibitor CombinationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)International Journal of Antimicrobial Agents, 2014
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative BacilliDrugs, 2013
- Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolatesInternational Journal of Antimicrobial Agents, 2009
- The Complex Formed Between Tet Repressor and Tetracycline-Mg2|ihsbop|+Reveals Mechanism of Antibiotic ResistanceJournal of Molecular Biology, 1995